Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Sativex Delta-9-tetrahydrocannabinol/cannabidiol Pain, Neuropathic (adjunctive) in MS. Do not list Complete
Sativex Delta-9-tetrahydrocannabinol/cannabidiol Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) Do not list Complete
Saxenda liraglutide Chronic weight management in adults Do not reimburse Complete
Scemblix asciminib Philadelphia chromosome-positive chronic myeloid leukemia Reimburse with clinical criteria and/or conditions Complete
Sebivo Telbivudine Hepatitis B (chronic) Do not list Complete
Seebri Glycopyrronium bromide Chronic obstructive pulmonary disease List with criteria/condition Complete
Segluromet ertugliflozin and metformin hydrochloride Diabetes mellitus, Type 2 Do not reimburse Complete
Semglee insulin glargine Diabetes mellitus, Type 1 & 2 Withdrawn
Sensipar Cinacalcet hydrochloride Secondary hyper-parathyroidism in chronic kidney disease Do not list Complete
Signifor Pasireotide diaspartate Cushing’s disease Do not list Complete